Published in Cancer Weekly, September 3rd, 2002
Patients treated with Zoladex adjuvant to radiotherapy showed a significant difference in overall survival compared with patients given radiotherapy alone (HR=3D0.51; 95% CI=3D0.36-0.73; p<0.0001). The 5-year survival estimates were 78% in the adjuvant therapy group and 62% in the radiotherapy alone group.
Patients treated with Zoladex adjuvant to radiotherapy also showed a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.